Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Sigr	e of entity	ABN/ARSN		
	ma Pharmaceuticals Limited	15 088 417 403		
We	(the entity) give ASX the following	information.		
Info	ormation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 3D dated 2 October 2014)		
	al of all shares/units bought e been received, before, and	-	which acceptances Previous day	
3	Number of shares/units bought back or if buy-back is an equal	98,592,095	89,132	
	access scheme, in relation to which acceptances have been received			
	which acceptances have been			

		Before p	revious	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.8400
		Lowest p \$0.5600	nrice	price paid:	Lowest price paid: \$0. 8400
			рпос		Highest price allowed under rule 7.33: \$0.9133

How many shares/units may still be bought back?

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

(Director/Company secretary)

Sign here: Date: 8 May 2015

Print name: SUE MORGAN

== == == ==